 maintain or slightly improve the outcome at one year. That's not what the patients are interested in. I don't believe that that will encourage pharmaceutical companies and investors to support transplant. So I think we need an outcome that measures something important to patients, which is a longer-term outcome as well as a quality-of-life outcome.